Nonsteroidal anti-inflammatory drugs (NSAIDs) are effective medications for the treatment of many chronically painful medical conditions. However, it is estimated that 25% of all serious adverse drug reactions involve NSAIDs, with more than 100,000 hospitalizations and 16,000 deaths occurring annually due to NSAID-induced gastrointestinal (GI) events. Advanced age; concurrent anticoagulant, aspirin, corticosteroid, or antacid use; and a history of cardiovascular disease, peptic ulcer disease, or GI hemorrhage all increase the risk of NSAID-induced gastropathy. Home care patients often have many of these characteristics. This article will provide evidence-based information about interventions that can reduce patients’ NSAID-induced gastropathy risk, including knowledge gained from a home care–specific study.
Bombardier, C. , Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., Kvien, T. K., & Schnitzer, T. J. (2000). Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New England Journal of Medicine, 343, 1520-1528.
2.
Day, R. , Morrison, B., Luza, A., Castaneda, O., Strusberg, A., Nahir, M., Helgetveit, K. B., Kress, B., Daniels, B., Bolognese, J., Krupa, D., Seidenberg. B., & Ehrich, E.A. (2000). A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Archives of Internal Medicine, 160, 1781-1787.
3.
Ehsanullah, R.S.B. , Page, M. C., Tildesley, G., & Wood, J. R. (1988). Prevention of gastroduodenal damage induced by nonsteroidal anti-inflamatory drugs: Controlled trial of ranitidine. British Medical Journal, 297, 1017-1021.
4.
Fries, J. F. (1991). NSAID gastropathy: The second most deadly rheumatic disease?Journal of Rheumatology, 18, 6-10.
5.
Hawkey, C. J. , Karrasch, J. A., Szczepanski, L., Walker, D. G., Barkun, A., Swannell, A. J., & Yeomans, N. D. (1998). Omprezole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs. New England Journal of Medicine, 338, 727-734.
6.
Hubbard, R. , Geis, G. S., Woods, E. (1999). Efficacy, tolerability, and safety of celecoxib, a specific COX-2 inhibitor, in osteoarthritis. Arthritis Rheum41(Suppl. 9), S196-S196. Abstract 982.
7.
Kozuh, J. L. (2000). NSAIDs and antihypertensives: An unhappy union. American Journal of Nursing, 100(6), 40-43.
8.
Lichtenstein, D. R. , Syngal, S., & Wolfe, M. M. (1995). Nonsteroidal anti-inflammatory drugs and the gastrointestinal tract: The double edged sword. Arthritis & Rheumatism, 38, 5-18.
9.
Needleman, P. , & Iskson, P. C. (1997). The discovery and function of COX-2. Journal of Rheumatology, 24(Suppl. 4A), 6S-8S.
10.
Oddis, C. V. (1996). New perspectives on osteoarthritis. American Journal of Medicine, 100(Suppl. 2A), 105S-115S.
11.
OTC analgesics in adult patients—An overview. (2001). Retrieved March 27, 2001, from the World Wide Web: http://www.ama-assn.org/cmeselec/media/hmb2.pdf
12.
Peloso, P. M. (2000). NSAIDs: A Faustian bargain. American Journal of Nursing, 100(6), 34-39.
13.
Pepper, G. A. (2000). Nonsteroidal anti-inflammatory drugs: New perspectives on a familiar drug class. Nursing Clinics of North America, 55, 223-244.
14.
Roth, S. H. (1996). NSAID gastropathy: A new understanding. Archives of Internal Medicine, 156, 1623-1628.
15.
Silverstein, F. E. , Faich, G., Goldstein, J. L., Simon, L. S., Pincus, T., Whelton, A., Makuch, R., Eisen, G., Agrawal, N. M., Stenson, W. F., Burr, A. M., Zhao, W. W., Kent, J. D., Lefkowith, J. B., Verburg, K. M., & Geis, G. S. (2000). Gastrointestinal toxicity with celecoxib vs nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis—the CLASS study: A randomized controlled trial. Journal of the American Medical Association, 284, 1247-1255.
16.
Silverstein, F. E. , Graham, D. Y., Senior, J. R., Davies, H. W., Struthers, B. J., Bittman, R. M., & Geis, G. S. (1995). Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis on nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Annals for Internal Medicine, 123, 241-249.
17.
Simon, L. S. , Hatoum, H. T., Bittman, R. M., Archambault, W. T., & Polisson, R. P. (1996). Risk factors for serious nonsteroidal-induced gastrointestinal complications: Regression analysis of the MUCOSA Trial. Family Medicine, 28, 204-210.
18.
Singh, G. ,& Triadafilopoulos, G. (1999). Epidemiology of NSAID-induced gastrointestinal complications. Journal of Rheumatology, 26(Suppl 26), 18-24.
19.
Singh, G. , Ramey, D. R., Morfeld, D., Shi, H., Hatoum, H. T., & Fries, J. F. (1996). Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. Archives of Internal Medicine, 156, 1530-1536.
20.
Vane, J. R. ,& Botting, R. M. (1995). New insights into the mode of action of anti-inflammatory drugs. Inflammation Research, 44, 1-10.
21.
Wilcox, C. M. , & Clark, W. S. (1997). Features associated with painless peptic ulcer bleeding. American Journal of Gastroenterology, 92, 12189-12192.
22.
Wolfe, M. M. , Lichtenstein, D. R., & Singh, G. (1999). Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. New England Journal of Medicine, 340, 1888-1899.
23.
Wynne, H. A. , & Long, A. (1996). Patient awareness of the adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs). British Journal of Pharmacology, 42, 253-256.
24.
Yeomans, N. D. , Tulassay, Z., Juhasz, L., Racz, I., Howard, J. M., van Rensburg, J., Swannell, A. J., & Hawkey, C. J. (1998). A comparison of omeprazoe with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. New England Journal of Medicine, 338, 719-726.
